Detalles de la búsqueda
1.
Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials.
PLoS Med
; 17(11): e1003323, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-33147277
2.
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma.
Blood
; 132(6): 587-597, 2018 08 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29884741
3.
Microhomology-mediated end joining drives complex rearrangements and overexpression of MYC and PVT1 in multiple myeloma.
Haematologica
; 105(4): 1055-1066, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31221783
4.
Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytes.
Br J Haematol
; 184(4): 578-593, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30408155
5.
Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
Lancet
; 389(10068): 519-527, 2017 02 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28017406
6.
Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma.
Haematologica
; 103(6): 1047-1053, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29567784
7.
End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma.
Future Oncol
; 13(13): 1181-1193, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-28395525
8.
High-risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse.
Br J Haematol
; 195(2): 283-286, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34244996
9.
Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120).
Blood
; 123(1): 78-85, 2014 Jan 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-24144643
10.
Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3.
Blood
; 121(10): 1819-23, 2013 Mar 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-23305732
11.
Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.
Blood
; 121(23): 4753-7, 2013 Jun 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-23603914
12.
Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120).
Haematologica
; 100(9): 1214-21, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26022710
13.
Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.
Blood
; 120(8): 1597-600, 2012 Aug 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-22674807
14.
Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma.
Haematologica
; 98(7): 1147-53, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23716540
15.
Early phase trial design for assessing several dose levels for toxicity and efficacy for targeted agents.
Clin Trials
; 10(3): 422-9, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23529697
16.
IASLC Lung Cancer Staging Project: The New Database to Inform Revisions in the Ninth Edition of the TNM Classification of Lung Cancer.
J Thorac Oncol
; 18(5): 564-575, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36773775
17.
Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.
Blood
; 115(21): 4168-73, 2010 May 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-20124509
18.
Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy.
Blood
; 116(8): 1220-7, 2010 Aug 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-20501894
19.
Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents.
Haematologica
; 97(11): 1761-7, 2012 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-22689675
20.
The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma.
Haematologica
; 102(9): e364-e367, 2017 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28550191